» Articles » PMID: 15288963

Few Modifications of the Cobas Amplicor HIV Monitor 1.5 Test Allow Reliable Quantitation of HIV-1 Proviral Load in Peripheral Blood Mononuclear Cells

Overview
Journal J Virol Methods
Specialty Microbiology
Date 2004 Aug 4
PMID 15288963
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Recent studies have suggested that monitoring the amount of HIV provirus in peripheral blood mononuclear cells (PBMCs) may be a useful end point for HAART where, in combination with plasma viral load, it provides additional information as to the possibility of virus eradication. In the present study, a modified version of the Cobas Amplicor HIV-1 Monitor test (CAHIM), currently used to quantify plasma viremia, have been evaluated to also measure the amount of proviral DNA in PBMCs. The analytical and clinical performance of the modified CAHIM test was assessed by quantifying different amounts of a standard HIV-DNA preparation obtained from the 8E5 cell line and by analysing 165 patients and controls samples. In these experiments, the modified test, that showed a linear dynamic range from 1.7 to 4.7 log10 copies/10(6) cells (r = 0.99) with a maximum CV of 20%, proved able to detect and quantify HIV-DNA in all but one clinical samples, with concentrations varying from 1.3 to 3.8 log10 copies/10(6) cells. During anti-retroviral treatment, the assay revealed different proviral DNA time courses associated with viral load changes and inversely correlated with CD4+ cells count. As expected, HIV-DNA was always detectable even when plasma viremia fell below the CAHIM cut-off. The modified CAHIM test specificity was confirmed by testing 20 HIV-negative samples in triplicates. Taken together, the data showed that the modified CAHIM test can be used to monitor HIV proviral DNA changes during HAART and can help in investigating further the clinical use of this marker.

Citing Articles

Quantification of Total HIV DNA as a Marker to Measure Viral Reservoir: Methods and Potential Implications for Clinical Practice.

Belmonti S, Di Giambenedetto S, Lombardi F Diagnostics (Basel). 2022; 12(1).

PMID: 35054206 PMC: 8774405. DOI: 10.3390/diagnostics12010039.


Impact of Early Antiretroviral Therapy on Detection of Cell-Associated HIV-1 Nucleic Acid in Blood by the Roche Cobas TaqMan Test.

Jagodzinski L, Manak M, Hack H, Liu Y, Malia J, Freeman J J Clin Microbiol. 2019; 57(5).

PMID: 30842229 PMC: 6498003. DOI: 10.1128/JCM.01922-18.


Clinical Relevance of Total HIV DNA in Peripheral Blood Mononuclear Cell Compartments as a Biomarker of HIV-Associated Neurocognitive Disorders (HAND).

Ruhanya V, Jacobs G, Glashoff R, Engelbrecht S Viruses. 2017; 9(11).

PMID: 29088095 PMC: 5707531. DOI: 10.3390/v9110324.


Total HIV-1 DNA, a Marker of Viral Reservoir Dynamics with Clinical Implications.

Avettand-Fenoel V, Hocqueloux L, Ghosn J, Cheret A, Frange P, Melard A Clin Microbiol Rev. 2016; 29(4):859-80.

PMID: 27559075 PMC: 5010749. DOI: 10.1128/CMR.00015-16.


A more precise HIV integration assay designed to detect small differences finds lower levels of integrated DNA in HAART treated patients.

Yu J, Wu T, Liszewski M, Dai J, Swiggard W, Baytop C Virology. 2008; 379(1):78-86.

PMID: 18649912 PMC: 2610678. DOI: 10.1016/j.virol.2008.05.030.